Send by ABC News

AP — Bristol-Myers Squibb Co. posted a slight decline in third-quarter profit as its restrained spending was offset by flat sales of its drugs, lower [...]

Send by BusinessWeek

The drugmaker Bristol-Myers Squibb Co. reported a better-than-expected profit, but revenue fell short of forecasts. Sales were hurt by the health care [...]

Send by BusinessWeek

Drugmaker Bristol-Myers Squibb Co. said Monday federal regulators have approved its hepatitis B treatment Baraclude for patients with a more severe form of [...]

Send by Zacks.com

Oct 26, 2010 (SmarTrend News Watch via COMTEX) -- Officials from Bristol Myers Squibb Co. (NYSE:BMY) said Tuesday that the company received a warning letter [...]

Send by Middle East North Africa Finan

Bristol-Myers Squibb BMY is projected to post earnings of 53 cents a share in the third quarter. DreamWorks DWA is forecast to report earnings of 34 cents a [...]

Send by Wall Street Journal

Bristol-Myers Squibb Co.'s third-quarter profit declined slightly from a year earlier, amid flat sales, lower costs and bigger rebates to the US government [...]

Send by ABC News

AP By AP BALANCING ACT: Slight spending cuts at drugmaker Bristol-Myers Squibb Co. are offset by flat sales, bigger government discounts and other factors, [...]

BMS is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious [...]

View the basic BMY stock chart on Yahoo! Finance. Change the date range, chart type and compare Bristol-Myers Squibb Company Co against other companies. [...]

Bristol-Myers Squibb at UBS Global Life Sciences Conference Bristol-Myers Squibb American Society of Clinical Oncology (ASCO) 2010 Investor Briefing [...]

The Bristol-Myers Squibb Patient Assistance Foundation, Inc. is a non-profit organization. The Foundation was established in 1998 to provide temporary [...]

What sets Bristol-Myers Squibb apart? It's our focus on finding innovative medicines to combat serious diseases, and getting them to patients faster and [...]

Home About Us Research & Development Our Medicines Working for BMSA Social Responsibility News Contact Us Site Map. Mini Homepage Image, Mini About [...]

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients [...]

Eligible patients who need help paying for their Bristol-Myers Squibb medicines Click here for trademark information on Bristol-Myers Squibb products. [...]

Send by Liz Jones Hollis

Bristol-Myers Squibb to Acquire ZymoGenetics * Builds on Long-standing Commitment to Virology * Gains Full Rights to Promising Phase II Hepatitis C Biologic, Pegylated-Interferon Lambda Read more [...]

Send by www.businessweek.com

Bristol-Myers Squibb Co.’s third- quarter profit increased 6.4 percent, topping analysts’ estimates as the drugmaker cut costs. Sales missed estimates after the U.S. health-care overhaul reduced reimbursements. [...]

Bristol-Myers Squibb (BMY), which sells blood thinner Plavix, today reported better-than-expected third quarter earnings, mainly due to cost cuts. Revenue, however, fell short of expectations. Continue reading Bristol-Myers Squibb [...]

Exelixis Expands Collaboration With Bristol-Myers Squibb. Pharmaceuticals: New deals accompany the biotech's increased focus on compounds in late-stage development. [...]

Bristol-Myers Squibb Company (BMY) is scheduled to report Q3-2010 results on Tuesday, October 26, 2010. In the last four quarters ending June 2010, the company's reported EPS exceeded analysts' consensus estimates in the range of 1.69% [...]

Send by www.omaha.com

Bristol-Myers Squibb Co. posted a slight decline in third-quarter profit Tuesday as its restrained spending was offset by flat sales of its drugs, lower income from its partners and bigger discounts to government because of the [...]

Send by gareth.macdonald@decisionnews.

Global biopharmaceutical company, Bristol-Myers Squibb will buy ZymoGenetics for $885m to become owner of a hepatitis C drug the companies are jointly developing. [...]

Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has completed its previously announced acquisition of ZymoGenetics, Inc. (NASDAQ: ZGEN). As a result of the transaction, ZymoGenetics has become a wholly-owned subsidiary [...]

Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $26.99 to a high of $27.23. Yesterday, the shares gained 0.74%, which took the trading range above the 3-day high of $27.17 on volume of 8.1 million [...]

Bristol-Myers Squibb at UBS Global Life Sciences Conference Bristol-Myers Squibb American Society of Clinical Oncology (ASCO) 2010 Investor Briefing [...]